Results of the INHALE-3 extension study: inhaled technosphere insulin plus insulin degludec in T1D

A new study in the peer-reviewed journal Diabetes Technology & Therapeutics (DTT) evaluated the effects of a regimen of inhaled technosphere insulin (TI) and insulin degludec over 30 weeks and its potential to reduce post-meal hyperglycemia in adults with type 1 diabetes. Click here to read the article now. TI has a more rapid onset of action than rapid-acting insulin analogues.

Roy Beck, MD, PhD, from the JAEB Center for Health Research, and coauthors, reported that HbA1c levels were sustained over a 30-week period using a TI-degludec regimen after patients switched from either automated insulin delivery (AID) or multiple daily injections (MDI). Mean time in range was 52%+18% at baseline, 53+20% at 17 weeks, and 54+20% at 30 weeks.

The investigators stated that, “43% of participants expressed interest in continuing the TI-degludec regimen rather than returning to their pre-study regimen, even a third who were previously using AID. This finding plus the results of the RCT and extension phase provide support for TI being an available option for people with T1D.”

“Afrezza, the TI insulin, showed similar efficacy in patients who transitioned to MDI from using an AID system as reported by Beck et al.,” says Satish Garg, MD, Editor-in-Chief of Diabetes Technology & Therapeutics, from University of Colorado Denver, Barbara Davis Center for Diabetes.

About the Journal
Diabetes Technology & Therapeutics (DTT) is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Led by Editor-in-Chief Satish Garg, MD, University of Colorado Denver, Barbara Davis Center for Diabetes, the Journal covers breakthrough technologies and new therapeutic drug classes, behavioral aspects and approaches to diabetes care, and the latest advancements and applications of new and emerging technologies including continuous glucose monitoring, alternate insulin delivery methods, artificial pancreas, telemedicine and computerized case management, new insulins with ultra-rapid onset of action, and detection and prevention of hypoglycemia. Tables of contents and a free sample issue may be viewed on the Diabetes Technology & Therapeutics (DTT) website. DTT is the official journal of the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD).

About Mary Ann Liebert, Inc., a Sage Company
Mary Ann Liebert, Inc. is a global media company dedicated to publishing and delivering impactful peer-reviewed research in biotechnology & life sciences, specialized clinical medicine, public health and policy, and technology & engineering. Since its founding in 1980, the company has focused on providing critical insights and content that empower researchers and clinicians worldwide to drive innovation and discovery.